Social Behavior Research & Health
June 3, 2019
Zahra Ghasemi, Mohammad Bagher Kajbaf
Background: In recent years, the incidence of depression in people, especially women, has been growing, making it essential to study psychological correlates with the disorder. Therefore, the present study was conducted to investigate the relationship of mindfulness, psychological hardiness and spirituality with depression in mothers. Methods: The statistical population of this correlational...
International Journal of Yoga Therapy
May 30, 2019
Amisha Klawonn, Dana Kernan, James Lynskey
34 citations
Abstract Graduate healthcare students can experience stress that affects their ability to perform academically and clinically, decreases empathy, and affects their well-being and clinical competence. The purpose of the current study was to determine the effects of a seminar on a yoga-inspired biopsychosocial-spiritual model of self-care on perceived levels of anxiety, self-compassion,...
May 29, 2019
Michael Lifshitz, Matthew D. Sacchet, Julia M. Huntenburg et al.
1 citation
Major depressive disorder (MDD) is associated with abnormal functional interactions among large-scale brain networks. Here we report findings from a randomized, active-controlled trial examining whether mindfulness-based therapy can regulate specific patterns of resting-state functional connectivity in clinically depressed patients. We show that a brief, clinically effective mindfulness...
JAMA
May 24, 2019
Ole Köhler‐forsberg, Cristina Cusin, Andrew A. Nierenberg
18 citations
This Viewpoint discusses recent evidence documenting benefits of nonpharmacological and drug therapies for major depressive disorder including exercise, Mediterranean diet and structured dietary support, ketamine and esketamine, anti-inflammatory drugs, brexanolone, and psilocybin.
New England Journal of Medicine
May 22, 2019
Jean Kim, Tiffany R. Farchione, Andrew Potter et al.
Esketamine for Treatment-Resistant Depression The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset...
American Journal of Psychiatry
May 21, 2019
Vanina Popova, Ella Daly, Madhukar H. Trivedi et al.
879 citations
OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active...
Frontiers in Psychology
May 17, 2019
Anna Dora Frostadottir, D. Dorjee
Objectives: Over the past decade there has been an increasing interest in exploring self-compassion as a related and complementary construct to mindfulness. Increases in self-compassion may predict clinical outcomes after MBCT and cultivation of compassion toward self and others is central to CFT. This pilot study compared the impact of MBCT applying implicit self-compassion instructions and...
May 14, 2019
Ketamine has emerged as the prototypical rapid-acting antidepressant. Early efficacy studies showed a high rate of response (64% to 71%) to a single dose of ketamine among individuals with treatment-resistant depression. Later clinical reports of the effectiveness of ketamine in clinical samples demonstrated a response rate of approximately 50%. This discrepancy between efficacy and...
Molecular Neurobiology
May 2019
Wenyan Cui, Yuping Ning, Wu Hong et al.
Depression is a worldwide illness with a significant impact on both family and society. Conventional antidepressants are ineffective for more than 30% of patients. In such patients, who have what is called treatment-resistant depression (TRD), inflammatory biomarkers are expressed excessively in both the central nervous system (CNS) and the peripheral blood. Ketamine, a glutamate receptor...
The Canadian Journal of Psychiatry
May 1, 2019
Shera Hosseini, Mark Oremus
Objectives: This study was conducted to review the current state of evidence on the association between age of initiation of cannabis use and symptoms of psychosis, depression, or anxiety among youth under 25 years of age. Methods: We conducted a systematic review of articles published prior to March 2018 by searching OVID MEDLINE, PsycINFO, EMBASE, and the references of included studies. We...